Correspondence

A transgenic mouse model to inducibly target prosurvival Bcl2 proteins with selective BH3 peptides *in vivo*

EF Lee^{1,2}, M Takiguchi¹, A Pettikiriachchi¹, M Evangelista¹, DCS Huang^{1,2}, RA Dickins^{*,1,2} and WD Fairlie^{*,1,2}

Cell Death and Disease (2015) 6, e1679; doi:10.1038/cddis.2015.54; published online 12 March 2015

Dear Editor,

BH3-mimetic drugs that antagonize Bcl-2 family prosurvival proteins are effective against some cancers, particularly those with abnormally high expression of the prosurvival protein target.¹ Despite the recent success of BH3-mimetics targeting Bcl-2, Bcl-x_L and Bcl-w, mechanism-based cell killing *in vivo* by targeting other important prosurvival proteins such as Mcl-1 or Bfl-1 has yet to be demonstrated. In the absence of small molecules targeting these prosurvival proteins, BH3-domain peptides, the prototypes for this class of drug, are useful because their binding specificity profile can be manipulated.^{2,3} Such peptides have been applied in *in vitro* studies to validate the targeting of particular prosurvival proteins in certain tumor types.^{4,5} However, *in vivo* applications require technically challenging chemical modifications of peptides, and while mouse xenograft models of virally-infected BH3 domain-expressing tumor cells can be used, this does not allow evaluation of effects of the ligand on normal tissues.

Here we have generated transgenic mice in which peptide-based BH3 ligands can be inducibly expressed to evaluate their effects *in vivo* and provide proof-of-principle for similar-acting drugs. To achieve this we adapted a previously described strategy allowing FLP-recombinase-mediated insertion of an expression cassette at an *frt* 'landing pad' at the type I collagen (*Col1a1*) locus in mouse embryonic stem cells.⁶ The cassette comprises sequences encoding a BH3-domain protein under control of a tetracycline (tet)-regulated element (TRE) promoter. To develop a system that is broadly applicable to BH3 domains with different specificities, we employed the Bim_S BH3-only protein as a scaffold in which BH3 domains with different specificities could replace the native BH3 sequence (Figure 1a). Bim_S is an intrinsically unstructured protein that tolerates extensive mutation of its BH3 sequence, and Bim_SBH3 chimeras display the prosurvival protein specificity profile of the replacement BH3 domain.⁷ In this study we focussed on the BH3 domain of Bad because it targets the prosurvival proteins Bcl-2, Bcl-x_L and Bcl-w.⁷ Hence Bim_SBad expression should mimic the BH3-mimetics ABT-737 and ABT-263 that have been extensively studied *in vivo*.¹

We generated TRE-Bim_SBad transgenic mice and crossed them to mice expressing the rTA (tet-on) transactivator under the control of the cytomegalovirus (CMV) promoter, which provides high-level expression in many tissues including blood.⁸ Bitransgenic mice were then treated with doxycycline (Dox) to induce Bim_SBad expression (Figure 1a). Western blot analysis verified Dox-inducible transgene expression in white blood cells of Bim_SBad; CMV-rTA bitransgenic mice (Figure 1b). As ABT-737/263 induces thrombocytopenia in mice and humans due to antagonism of Bcl-x_L, we measured platelet levels as a biomarker for functional expression of the ligand.¹ Notably, blood cell analysis of these mice revealed a significant reduction (~65% decrease) in platelet counts (Figure 1c and d), a degree of thrombocytopenia comparable with that seen in patients administered with ABT-263.⁹ Importantly, platelet counts rebounded to normal levels following removal of Dox for 7 days (Figure 1d), illustrating the reversibility of the system. We also generated an additional transgenic mouse strain allowing inducible expression of a Bim_SBad construct possessing a BH3 sequence mutation (Bim_SBad^{mut}; Figure 1a) that decreases its affinity for Bcl-x_L by > 40-fold (K_D 8.5 nM *versus* < 0.2 nM as measured by surface plasmon resonance). Induction of Bim_SBad^{mut} expression (Figure 1b) did not alter blood cell or platelet counts (Figure 1d), indicating that the thrombocytopenia observed in Bim_SBad mice is due to Bcl-x_L inhibition. These data provide the first evidence that BH3-only proteins can be inducibly expressed in a mouse model, effectively mimicking at least one functional consequence (reduced platelet counts) seen in mice and humans treated with BH3-mimetic drugs of similar specificity. We envisage multiple applications for similarly engineered mice. For example, tet-regulated expression of different Bim_S variants in mice could reveal toxicities associated with neutralization of their prosurvival protein targets (individually or in combination), and tissue-specific effects could be addressed by crossing onto mice where rTA expression is driven by different promoters. Moreover, mice crossed to different tumor-prone models could provide *in vivo* evidence for the tumor-killing efficacy associated with different BH3 specificities not yet available through small molecule

¹Structural Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia and ²Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia

*Corresponding author: WD Fairlie or RA Dickins, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3052, Victoria, Australia. Tel: +61 3 9345 2689 or +61 3 9345 2482; Fax: +61 3 9345 2686; E-mails: fairlie@wehi.edu.au or rdickins@wehi.edu.au

c

	Doxycycline 7 days		
	+/+;+/+ (n=7)	TRE-Bim _S Bad (n=15)	TRE-Bim _S Bad; CMV-rtTA (n=17)
Erythrocytes (x10 ⁶ μL ⁻¹)	11.19 ± 0.17	11.32 ± 0.20	11.13 ± 0.13
Hematocrit (%)	54.91 ± 1.05	55.75 ± 0.56	55.48 ± 0.65
MCV (femtolitres)	49.07 ± 0.44	48.46 ± 0.30	49.85 ± 0.34
Leukocytes (x10 ³ μL ⁻¹)	9.81 ± 0.64	10.29 ± 0.53	9.12 ± 0.37
Neutrophils (x10 ³ μL ⁻¹)	0.91 ± 0.20	0.80 ± 0.24	1.19 ± 0.20
Lymphocytes (x10 ³ μL ⁻¹)	8.47 ± 0.55	8.93 ± 1.93	7.12 ± 1.12
Monocytes (x10 ³ μL ⁻¹)	0.17 ± 0.047	0.17 ± 0.058	0.25 ± 0.030
Platelets (x10 ³ μL ⁻¹)	1240 ± 61.82	1200 ± 36.12	439 ± 30.53****
MPV (femtolitres)	6.82 ± 0.23	6.93 ± 0.12	7.42 ± 0.098

Figure 1 Expression of Bim₅Bad reduces platelet levels in mice. (a) Schematic of the CMV-rtTA and TRE-Bim₅Bad transgenes. Upon Dox treatment of bitransgenic mice, the rtTA (tet-on) protein transactivates the TRE promoter to drive expression of N-terminally FLAG tagged Bim₅Bad. Targeting vectors were generated by cloning MluI-flanked FLAG-Bim₅Bad/Bim₅Bad^{mut} PCR amplicons into the MluI site of a modified version of the pgkATGftr vector⁶ in which the TRE promoter has been replaced with TREtight. BH3 domain numbering refers to the amino acid residue position within the respective Bim₅ or Bad protein sequences. The BadBH3 residue in red (F121) was mutated to alanine in the Bim₅Bad^{mut} mice. Targeted ES cell clones were injected into C57Bl/6 blastocysts and chimeras crossed to C57Bl/6 female mice. All mouse colonies were maintained by C57Bl/6 backcrossing. (b) Western blot of white blood cells isolated from TRE-Bim₅Bad/Bim₅Bad^{mut}, CMV-rtTA bitransgenic mice or wild-type or Bim₅Bad/Bim₅Bad^{mut} single transgenic control mice following 7 days of Dox food (600 mg/kg). Blood (100 μ l) was cleared of red blood cells by 10-fold dilution in red cell lysis buffer for 5 min followed by centrifugation. The white blood cell-containing pellet was then resuspended in lysis buffer (20 mM Tris pH 7.4, 135 mM NaCl, 1.5 mM MgCl₂, 1 mM EGTA, 1% Triton X100 and 10% glycerol) for 1 h on ice, followed by centrifugation. The supernatant was then analyzed by Western blot probed with an anti-FLAG antibody and reprobed with anti- β -actin as loading control. * Indicates a non-specific band (c) Blood cell parameters after Dox treatment of bitransgenic and control animals for 7 days. **** $P < 0.0001$ (t-test) compared with littermate controls (d) Platelet levels in TRE-Bim₅Bad bitransgenic mice treated with Dox for 7 days rebound to normal levels after 7 days without Dox treatment. No changes in platelet levels were observed in Bim₅Bad^{mut} mice following Dox treatment

drugs, and extended to studies on combination therapies with existing drugs.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This work was supported by grants and fellowships from the NHMRC of Australia (Project Grant 1041936 to WDF and 575573 to RAD, Program grant 1016701 to DCSH, Career Development Fellowship 1024620 to EFL, Research Fellowship to DCSH), Cancer Council of Victoria Grant-In-Aid 1057949 to WDF and EFL, Leukemia and Lymphoma Society (Specialized Centers of Research Grant), and a Sylvia and Charles Viertel Senior Research Fellowship to RAD. Infrastructure support from NHMRC IRISS grant #361646 and the Victorian State Government OIS grant is gratefully acknowledged.

1. Roy MJ *et al.* *Br J Pharmacol* 2014; **171**: 1973–1987.
2. Lee EF *et al.* *J Cell Biol* 2008; **180**: 341–355.

3. Foight GW *et al.* *ACS Chem Biol* 2014; **9**: 1962–1968.
4. Glaser SP *et al.* *Genes Dev* 2012; **26**: 120–125.
5. Del Gaizo Moore V, Letai A. *Cancer Lett* 2013; **332**: 202–205.
6. Beard C *et al.* *Genesis* 2006; **44**: 23–28.
7. Chen L *et al.* *Mol Cell* 2005; **17**: 393–403.
8. Takiguchi M *et al.* *PLoS One* 2013; **8**: e54009.
9. Roberts AW *et al.* *J Clin Oncol* 2012; **30**: 488–496.

Cell Death and Disease is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution 4.0 International License**. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>